Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection

被引：5
作者：
Price, Jennifer C. [1 ]
Seaberg, Eric C. [2 ]
Phair, John P. [3 ]
Witt, Mallory D. [4 ]
Koletar, Susan L. [5 ]
Thio, Chloe L. [6 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Gastroenterol & Hepatol, 513 Parnassus Ave,S-357, San Francisco, CA 94143 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] Northwestern Univ, Dept Med, Div Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles Biomed Res Inst,Harbor UCLA, Torrance, CA USA
[5] Ohio State Univ, Dept Med, Div Infect Dis, Columbus, OH 43210 USA
[6] Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2016年 / 72卷 / 03期
基金：
美国国家卫生研究院;
关键词：
HIV; HBV; HCV; antiviral therapy; liver; hepatitis; APRI; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; MULTICENTER AIDS COHORT; PLATELET RATIO INDEX; FIBROSIS PROGRESSION; MONOINFECTED PATIENTS; COINFECTED PATIENTS; NONINVASIVE INDEX; HUMAN HEPATOCYTES; VIRAL-HEPATITIS;
D O I：
10.1097/QAI.0000000000000981
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
To determine the impact of highly active antiretroviral therapy (HAART) on liver disease, we analyzed changes in the aspartate aminotransferase to platelet ratio index (APRI) pre-and post-HAART initiation among 441 HIV-monoinfected and 53 HIV-viral hepatitis-coinfected men. Before HAART, APRI increased 17% and 34% among the HIV-monoinfected and coinfected men, respectively. With HAART initiation, APRI decreased significantly in men who achieved HIV RNA of <500 copies per milliliter: 16% for HIV-monoinfected and 22% for coinfected men. Decreases in APRI were dependent on HIV suppression. This protective effect of HAART decreased after 2 years, particularly in the HIV-monoinfected men.
引用
收藏
页码：319 / 323
页数：5
相关论文
共 50 条
  • [31] Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy
    Butler, Scott L.
    Valdez, Hernan
    Westby, Michael
    Perros, Manos
    June, Carl H.
    Jacobson, Jeffrey M.
    Levy, Yves
    Cooper, David A.
    Douek, Daniel
    Lederman, Michael M.
    Tebas, Pablo
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (03) : 297 - 303
  • [32] Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence
    Castilla, J
    Sobrino, P
    de la Fuente, L
    Noguer, I
    Guerra, L
    Parras, F
    AIDS, 2002, 16 (14) : 1945 - 1951
  • [33] Pulmonary radiological characteristics in patients with HIV infection at the time of highly active antiretroviral therapy (HAART)
    Schlossbauer, T.
    Schmidt, G. P.
    Bogner, J. R.
    Sing, A.
    Reiser, M. E.
    Becker-Gaab, C.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (08) : 341 - 346
  • [34] Impact of HIV infection and highly active antiretroviral therapy (HAART) on B cell subpopulations in children
    Singh, Ravinder
    Mukherjee, Aparna
    Singla, Mohit
    Vajpayee, Madhu
    Negi, Neema
    Kabra, Sushil K.
    Lodha, Rakesh
    Das, Bimal K.
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (07) : 1222 - 1231
  • [35] Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy
    Reus, S
    Portilla, J
    Gimeno, A
    Sánchez-Payá, J
    García-Henarejos, JA
    Martínez-Madrid, O
    Usó, J
    Roca, B
    Galindo, MJ
    López-Aldeguer, J
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2004, 22 (03): : 142 - 149
  • [36] Meta-analysis of adherence to highly active antiretroviral therapy in patients with HIV infection in China
    Wang, Yuan-Yuan
    Jin, Yu
    Chen, Chang
    Zheng, Wei
    Wang, Shi-Bin
    Ungvari, Gabor S.
    Ng, Chee H.
    Zhang, Xiaohua Douglas
    Wang, Gang
    Xiang, Yu-Tao
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2019, 31 (08): : 913 - 922
  • [37] Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States
    Cunningham, WE
    Markson, LE
    Andersen, RM
    Crystal, SH
    Fleishman, JA
    Golin, C
    Gifford, A
    Liu, HHH
    Nakazono, TT
    Morton, S
    Bozzette, SA
    Shapiro, MF
    Wenger, NS
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (02) : 115 - 123
  • [38] Fatal Disseminated Cryptococcus as the Initial Presentation of HIV Infection in the Era of Highly Active Antiretroviral Therapy
    Kovarik, Carrie L.
    Barnard, Jeffrey J.
    JOURNAL OF FORENSIC SCIENCES, 2009, 54 (04) : 927 - 929
  • [39] Fatty Liver and Hyperlipidemia in a Cohort of HIV-Positive Africans on Highly Active Antiretroviral Therapy
    Lesi, Olufunmilayo A.
    Soyebi, Kofoworola S.
    Eboh, Cosmas N.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2009, 101 (02) : 151 - 155
  • [40] Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy
    Sogaard, Ole S.
    Schonheyder, Henrik C.
    Bukh, Anne R.
    Harboe, Zitta B.
    Rasmussen, Thomas A.
    Ostergaard, Lars
    Lohse, Nicolai
    AIDS, 2010, 24 (09) : 1315 - 1322
12345